Dr. Christopher Lieu, MD
NPI: 1093852360
Total Payments
$39,870
2024 Payments
$2,788
Companies
17
Transactions
46
Medicare Patients
670
Medicare Billing
$158,445
Payment Breakdown by Category
Other$16,696 (41.9%)
Research$11,508 (28.9%)
Consulting$10,162 (25.5%)
Travel$859.35 (2.2%)
Food & Beverage$644.42 (1.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,412 | 6 | 33.6% |
| Unspecified | $11,508 | 8 | 28.9% |
| Consulting Fee | $10,162 | 6 | 25.5% |
| Honoraria | $3,150 | 3 | 7.9% |
| Travel and Lodging | $859.35 | 9 | 2.2% |
| Food and Beverage | $644.42 | 13 | 1.6% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $134.77 | 1 | 0.3% |
Payments by Type
General
$28,362
38 transactions
Research
$11,508
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $12,840 | 8 | $0 (2024) |
| Amgen Inc. | $8,003 | 5 | $0 (2023) |
| F. Hoffmann-La Roche AG | $6,575 | 4 | $0 (2024) |
| ARRAY BIOPHARMA INC | $3,150 | 3 | $0 (2021) |
| Covidien LP | $2,310 | 1 | $0 (2017) |
| Merrimack Pharmaceuticals, Inc. | $2,121 | 2 | $0 (2017) |
| Ipsen Bioscience Inc | $1,404 | 2 | $0 (2019) |
| Incyte Corporation | $1,230 | 1 | $0 (2020) |
| Merck Sharp & Dohme Corporation | $879.03 | 8 | $0 (2018) |
| Foundation Medicine, Inc. | $865.00 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,788 | 2 | F. Hoffmann-La Roche AG ($2,068) |
| 2023 | $10,574 | 5 | PFIZER INC. ($5,600) |
| 2022 | $8,700 | 4 | PFIZER INC. ($4,920) |
| 2021 | $4,750 | 6 | ARRAY BIOPHARMA INC ($3,150) |
| 2020 | $4,211 | 5 | F. Hoffmann-La Roche AG ($2,921) |
| 2019 | $3,012 | 5 | F. Hoffmann-La Roche AG ($1,587) |
| 2018 | $892.03 | 8 | Merck Sharp & Dohme Corporation ($844.03) |
| 2017 | $4,943 | 11 | Covidien LP ($2,310) |
All Payment Transactions
46 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | PFIZER INC. | BRAFTOVI (Drug) | Consulting Fee | Cash or cash equivalent | $720.00 | General |
| Category: ONCOLOGY | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $2,067.56 | Research |
| Study: AN OPEN-LABEL, MULTI-CENTER, DOSE-ESCALATION PHASE I STUDY, TO EVALUATE SAFETY, PHARMACOKINETICS AND THERAPEUTIC ACTIVITY OF RO6958688, A NOVEL T CELL BISPECIFIC ANTIBODY (TCB) TARGETING THE HUMAN CARCINOEMBRYONIC ANTIGEN (CEA) ON TUMOR CELLS AND CD3 ON T CELLS, ADMINISTERED INTRAVENOUSLY, IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC CEA(+) SOLID TUMORS. | ||||||
| 12/25/2023 | Amgen Inc. | LUMAKRAS (Drug), Vectibix | Consulting Fee | Cash or cash equivalent | $4,046.54 | General |
| Category: Oncology | ||||||
| 12/08/2023 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $5,600.00 | General |
| 11/28/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $865.00 | General |
| Category: Oncology | ||||||
| 08/28/2023 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $44.80 | General |
| 08/28/2023 | TAIHO ONCOLOGY, INC. | — | Travel and Lodging | In-kind items and services | $17.92 | General |
| 12/06/2022 | PFIZER INC. | MEKTOVI (Drug), BRAFTOVI | — | In-kind items and services | $780.00 | Research |
| Study: ENCORAFENIB AND BINIMETINIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 10/06/2022 | Amgen Inc. | Vectibix (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,780.00 | General |
| Category: Oncology | ||||||
| 06/29/2022 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | — | In-kind items and services | $3,200.00 | Research |
| Study: ENCORAFENIB AND BINIMETINIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 01/10/2022 | PFIZER INC. | BRAFTOVI (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: ENCORAFENIB AND BINIMETINIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 09/28/2021 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | — | In-kind items and services | $330.00 | Research |
| Study: ENCORAFENIB AND BINIMETINIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 09/25/2021 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | — | In-kind items and services | $940.00 | Research |
| Study: ENCORAFENIB AND BINIMETINIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 08/26/2021 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug) | Honoraria | Cash or cash equivalent | $630.00 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2021 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | — | In-kind items and services | $330.00 | Research |
| Study: ENCORAFENIB AND BINIMETINIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 05/07/2021 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug) | Honoraria | Cash or cash equivalent | $1,260.00 | General |
| Category: ONCOLOGY | ||||||
| 01/21/2021 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug) | Honoraria | Cash or cash equivalent | $1,260.00 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2020 | Ipsen Biopharmaceuticals, Inc | SOMATULINE DEPOT (Drug), ONIVYDE | Food and Beverage | In-kind items and services | $19.36 | General |
| Category: Oncology/Endocrinology | ||||||
| 10/16/2020 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $18.66 | General |
| Category: Oncology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $2,920.81 | Research |
| Study: A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY ADMINISTERED WITH BEVACIZUMAB ANDOR CHEMOTHERAPY IN PATIENTS WITH ADVANCED SOLID TUMORS • Category: BioOncology | ||||||
| 03/19/2020 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $1,230.00 | General |
| 02/06/2020 | Ipsen Biopharmaceuticals, Inc | SOMATULINE DEPOT (Drug), ONIVYDE | Food and Beverage | In-kind items and services | $22.44 | General |
| Category: Oncology/Endocrinology | ||||||
| 10/23/2019 | Ipsen Biopharmaceuticals, Inc | SOMATULINE DEPOT (Drug), ONIVYDE | Food and Beverage | In-kind items and services | $20.74 | General |
| Category: Oncology/Endocrinology | ||||||
| 09/30/2019 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,161.09 | General |
| Category: BioOncology | ||||||
| 09/30/2019 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $425.73 | General |
| Category: BioOncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ENCORAFENIB AND BINIMETINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $6,520 | 6 |
| A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY ADMINISTERED WITH BEVACIZUMAB ANDOR CHEMOTHERAPY IN PATIENTS WITH ADVANCED SOLID TUMORS | F. Hoffmann-La Roche AG | $2,921 | 1 |
| AN OPEN-LABEL, MULTI-CENTER, DOSE-ESCALATION PHASE I STUDY, TO EVALUATE SAFETY, PHARMACOKINETICS AND THERAPEUTIC ACTIVITY OF RO6958688, A NOVEL T CELL BISPECIFIC ANTIBODY (TCB) TARGETING THE HUMAN CARCINOEMBRYONIC ANTIGEN (CEA) ON TUMOR CELLS AND CD3 ON T CELLS, ADMINISTERED INTRAVENOUSLY, IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC CEA(+) SOLID TUMORS. | F. Hoffmann-La Roche AG | $2,068 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 157 | 340 | $194,784 | $37,847 |
| 2022 | 3 | 176 | 391 | $222,356 | $43,620 |
| 2021 | 3 | 167 | 375 | $189,094 | $41,597 |
| 2020 | 4 | 170 | 398 | $178,754 | $35,382 |
Total Patients
670
Total Services
1,504
Medicare Billing
$158,445
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 87 | 230 | $131,560 | $25,048 | 19.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 29 | 58 | $33,176 | $6,520 | 19.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 28 | 28 | $20,160 | $3,946 | 19.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 24 | $9,888 | $2,333 | 23.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 107 | 291 | $166,452 | $32,564 | 19.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 22 | 38 | $21,736 | $4,447 | 20.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 28 | 28 | $20,160 | $3,878 | 19.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 19 | 34 | $14,008 | $2,731 | 19.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 119 | 318 | $161,172 | $35,778 | 22.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 36 | 36 | $25,192 | $5,319 | 21.1% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 12 | 21 | $2,730 | $499.30 | 18.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 106 | 309 | $135,806 | $26,835 | 19.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 32 | 32 | $21,376 | $4,410 | 20.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 19 | 38 | $15,656 | $3,238 | 20.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 13 | 19 | $5,916 | $898.93 | 15.2% |
About Dr. Christopher Lieu, MD
Dr. Christopher Lieu, MD is a Student in an Organized Health Care Education/Training Program healthcare provider based in Aurora, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/30/2007. The National Provider Identifier (NPI) number assigned to this provider is 1093852360.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Lieu, MD has received a total of $39,870 in payments from pharmaceutical and medical device companies, with $2,788 received in 2024. These payments were reported across 46 transactions from 17 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($13,412).
As a Medicare-enrolled provider, Lieu has provided services to 670 Medicare beneficiaries, totaling 1,504 services with total Medicare billing of $158,445. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Medical Oncology
- Location Aurora, CO
- Active Since 01/30/2007
- Last Updated 06/20/2013
- Taxonomy Code 390200000X
- Entity Type Individual
- NPI Number 1093852360
Products in Payments
- BRAFTOVI (Drug) $9,610
- LUMAKRAS (Drug) $4,047
- Vectibix (Biological) $3,780
- ONIVYDE (Drug) $3,525
- Tecentriq (Biological) $2,921
- Emprint (Device) $2,310
- TECENTRIQ (Biological) $1,587
- KEYTRUDA (Biological) $879.03
- FOUNDATIONONE CDX (Device) $865.00
- MEKTOVI (Drug) $780.00
- Avastin (Biological) $124.98
- SOMATULINE DEPOT (Drug) $62.54
- Non-Covered Product (Drug) $48.00
- Lenvima (Drug) $18.66
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in Aurora
Dr. Adam Seidl, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $303,017
Student in an Organized Health Care Education/Training Program $303,017
Dr. David Johnson, Md Phd, MD PHD
Student in an Organized Health Care Education/Training Program — Payments: $113,555
Student in an Organized Health Care Education/Training Program $113,555
Brent Morel, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $78,262
Student in an Organized Health Care Education/Training Program $78,262
Frank Wydra, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $61,467
Student in an Organized Health Care Education/Training Program $61,467
Ryan Borne, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $40,513
Student in an Organized Health Care Education/Training Program $40,513
Tareq Yaseen
Student in an Organized Health Care Education/Training Program — Payments: $36,502
Student in an Organized Health Care Education/Training Program $36,502